Myovant Sciences Ltd.
(NYSE : MYOV)

( )
MYOV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.26%203.421.3%$752.26m
GILDGilead Sciences, Inc.
0.14%64.220.9%$374.75m
CELGCelgene Corporation
0.03%95.711.3%$325.97m
ALXNAlexion Pharmaceuticals, Inc.
7.53%123.492.0%$306.94m
ILMNIllumina, Inc.
-0.66%288.583.5%$277.12m
BIIBBiogen Inc.
-0.48%232.061.3%$268.05m
VRTXVertex Pharmaceuticals Incorporated
-1.16%184.241.9%$256.63m
EXASExact Sciences Corporation
-1.14%117.8724.1%$239.89m
REGNRegeneron Pharmaceuticals, Inc.
-0.93%295.022.6%$203.40m
AAgilent Technologies, Inc.
-0.69%71.701.6%$193.78m
SRPTSarepta Therapeutics, Inc.
-6.34%95.0714.7%$184.59m
BMRNBioMarin Pharmaceutical Inc.
-1.05%77.404.3%$97.47m
INCYIncyte Corporation
-0.59%85.562.5%$96.06m
GHDXGenomic Health, Inc.
-1.12%73.521.8%$85.99m
SGENSeattle Genetics, Inc.
-2.01%78.366.5%$79.57m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.